These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
337 related items for PubMed ID: 19168057
1. In vivo antagonism of the behavioral responses to L-3-,4-dihydroxyphenylalanine by L-3-,4-dihydroxyphenylalanine cyclohexyl ester in conscious rats. Matsushita N, Misu Y, Goshima Y. Eur J Pharmacol; 2009 Mar 01; 605(1-3):109-13. PubMed ID: 19168057 [Abstract] [Full Text] [Related]
2. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites. Alachkar A, Brotchie JM, Jones OT. Neurosci Res; 2010 Sep 01; 68(1):44-50. PubMed ID: 20542064 [Abstract] [Full Text] [Related]
3. Effects of a partial D2-like receptor agonist on striatal dopamine autoreceptor functioning in preweanling rats. Yoshida ST, Baella SA, Stuebner NM, Crawford CA, McDougall SA. Brain Res; 2006 Feb 16; 1073-1074():269-75. PubMed ID: 16427034 [Abstract] [Full Text] [Related]
4. The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats. Treseder SA, Rose S, Jenner P. Eur J Neurosci; 2001 Jan 16; 13(1):162-70. PubMed ID: 11135014 [Abstract] [Full Text] [Related]
5. L-3,4-dihydroxyphenylalanine-induced c-Fos expression in the CNS under inhibition of central aromatic L-amino acid decarboxylase. Shimamura M, Shimizu M, Yagami T, Funabashi T, Kimura F, Kuroiwa Y, Misu Y, Goshima Y. Neuropharmacology; 2006 Jun 16; 50(8):909-16. PubMed ID: 16504219 [Abstract] [Full Text] [Related]
8. Enhanced cortical dopamine output and antipsychotic-like effect of raclopride with adjunctive low-dose L-dopa. Eltayb A, Wadenberg ML, Svensson TH. Biol Psychiatry; 2005 Aug 15; 58(4):337-43. PubMed ID: 16102547 [Abstract] [Full Text] [Related]
9. Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats. Visanji NP, Millan MJ, Brotchie JM. Exp Neurol; 2006 Nov 15; 202(1):85-92. PubMed ID: 16814282 [Abstract] [Full Text] [Related]
10. Impact of L-dopa on striatal acetylcholine release: effects of 6-hydroxydopamine. Jackson D, Abercrombie ED, Zigmond MJ. J Pharmacol Exp Ther; 1993 Nov 15; 267(2):912-8. PubMed ID: 8246167 [Abstract] [Full Text] [Related]
11. Review on the relationship between nicotinic acetylcholine receptors and dopaminergic neurotransmission in the central nervous system--dopa is an endogenous neuroactive substance. Misu Y, Nakamura S, Goshima Y, Yue JL, Miyamae T, Kubo T. Yakubutsu Seishin Kodo; 1993 Jun 15; 13(3):199-210. PubMed ID: 8237136 [Abstract] [Full Text] [Related]
12. Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats. Buck K, Ferger B. Neurobiol Dis; 2008 Feb 15; 29(2):210-20. PubMed ID: 17920284 [Abstract] [Full Text] [Related]
13. Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat. Taylor JL, Bishop C, Walker PD. Pharmacol Biochem Behav; 2005 Aug 15; 81(4):887-93. PubMed ID: 16023708 [Abstract] [Full Text] [Related]
14. The effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L-DOPA and dopamine agonists in MPTP-treated primates. Treseder SA, Jackson M, Jenner P. Br J Pharmacol; 2000 Apr 15; 129(7):1355-64. PubMed ID: 10742291 [Abstract] [Full Text] [Related]
15. Regulation by D2 dopamine receptors of in vivo dopamine synthesis in striata of rats and mice with experimental parkinsonism. Richard MG, Bennett JP. Exp Neurol; 1994 Sep 15; 129(1):57-63. PubMed ID: 7925842 [Abstract] [Full Text] [Related]
16. L-DOPA cyclohexyl ester is a novel stable and potent competitive antagonist against L-DOPA, as compared to L-DOPA methyl ester. Misu Y, Goshima Y, Miyamae T, Furukawa N, Sugiyama Y, Okumura Y, Shimizu M, Ohshima E, Suzuki F. Jpn J Pharmacol; 1997 Nov 15; 75(3):307-9. PubMed ID: 9434265 [Abstract] [Full Text] [Related]
17. L-dihydroxyphenylalanine methyl ester is a potent competitive antagonist of the L-dihydroxyphenylalanine-induced facilitation of the evoked release of endogenous norepinephrine from rat hypothalamic slices. Goshima Y, Nakamura S, Misu Y. J Pharmacol Exp Ther; 1991 Aug 15; 258(2):466-71. PubMed ID: 1865350 [Abstract] [Full Text] [Related]
18. Endogenously released L-dopa itself tonically functions to potentiate postsynaptic D2 receptor-mediated locomotor activities of conscious rats. Yue JL, Nakamura S, Ueda H, Misu Y. Neurosci Lett; 1994 Mar 28; 170(1):107-10. PubMed ID: 7913742 [Abstract] [Full Text] [Related]
19. Non-effective dose of exogenously applied L-dopa itself stereoselectively potentiates postsynaptic D2 receptor-mediated locomotor activities of conscious rats. Nakamura S, Yue JL, Goshima Y, Miyamae T, Ueda H, Misu Y. Neurosci Lett; 1994 Mar 28; 170(1):22-6. PubMed ID: 7913743 [Abstract] [Full Text] [Related]
20. Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease. Segovia G, Mora F, Crossman AR, Brotchie JM. Mov Disord; 2003 Feb 28; 18(2):138-49. PubMed ID: 12539206 [Abstract] [Full Text] [Related] Page: [Next] [New Search]